ROLE OF THE CLINICAL PHARMACIST IN OPTIMISING OUTCOMES INHYPERTENSION MANAGEMENT

[1]ALUGANI MANISH GOUD, [2]DAGGULA VARSHA, [3]PENDAYALA KEERTHANA, [4]NAJAM UDDIN SIDDIQUI, [5]Dr.CHANDRASEKHARA RAO BARU.
[1]Student, [2]student, [3]student,[4]student,[5]principal.
[1]Pharmacy practice,
[1]Chilkur Balaji College of Pharmacy, Hyderabad, India

Abstract: Although blood pressure management rates are still below ideal worldwide, hypertension continues to be the most significant modifiable risk factor for cardiovascular morbidity and mortality. Clinical pharmacists are in a unique position to bridge the gap between guidelines and practical hypertension control because of their proficiency in pharmacology, patient communication, and health systems navigation. The epidemiology and pathophysiology of hypertension, the various difficulties in managing it, and the growing clinical responsibilities of pharmacists—from collaborative prescribing and medication therapy management to technology-enabled monitoring and special population care—are all covered in this thorough review. Pharmacist-led interventions regularly lower systolic blood pressure by 5–10 mmHg, improve medication adherence, lower cardiovascular risk, and improve guideline concordance, according to data from randomised controlled trials and systematic reviews. Critical discussion is held regarding future directions, such as pharmacogenomics, artificial intelligence, and increased prescribing authority, as well as obstacles to practice.

IndexTerms **- collaborative practice, antihypertensive therapy, blood pressure control, clinical pharmacist, pharmaceutical therapy management, hypertension, and patient adherence.**

INTRODUCTION

According to the 2017 ACC/AHA guidelines, hypertension is the most common chronic non-communicable disease in the world and the leading modifiable risk factor for cardiovascular disease (CVD), stroke, and renal failure. It is defined as sustained systolic blood pressure (SBP) ≥130 mmHg or diastolic blood pressure (DBP) ≥80 mmHg. [1] Less than 14% of affected individuals are thought to have sufficient blood pressure (BP) control worldwide, despite the availability of efficient, reasonably priced antihypertensive medications and well-established clinical practice standards. [2]

The complexity of hypertension management—encompassing lifestyle modification, individualised pharmacotherapy, monitoring, adherence optimisation, and management of comorbidities—demands a team-based approach that extends beyond the capacity of any single clinician. [3] Clinical pharmacists, with their specialised training in pharmacotherapy and direct patient care competencies, have emerged as critical members of the hypertension management team. [4] This review synthesises current evidence on the clinical pharmacist's role in optimising hypertension outcomes across a breadth of practice settings and patient populations.

Hypertension Epidemiology

About half of the 1.28 billion persons worldwide between the ages of 30 and 79 who suffer from hypertension are not aware that they have the condition. [2] Over 75% of people with hypertension live in low- and middle-income countries (LMICs), where the disorder is more common. However, access to treatment and infrastructure for blood pressure monitoring is still quite restricted. [5] Due to ageing populations, obesity epidemics, physical inactivity, and high-sodium diets, prevalence is increasing in high-income countries despite increased access to therapy. [6] According to the Global Burden of Disease research, high systolic blood pressure is the leading cause of premature death and disability-adjusted life years (DALYs) worldwide, accounting for around 10.8 million deaths each year. [7] The financial consequences are also startling: in the US alone, the annual direct and indirect expenses of hypertension surpass $131 billion, and these expenditures are expected to rise as the population ages. [8]

Pathophysiology

Genetic susceptibility, neurohumoral dysregulation, vascular dysfunction, and environmental variables combine intricately to cause hypertension. [9] Overactivation of the renin-angiotensin-aldosterone system (RAAS), which causes vasoconstriction, salt retention, and heart remodelling, is a key component in its pathophysiology. [10] The hemodynamic burden is exacerbated by sympathetic nervous system hyperactivity, which increases cardiac output and peripheral vascular resistance. [9] Endothelial dysfunction accelerates arterial stiffness and leads to the onset of hypertension as well as target organ damage in the heart, kidneys, brain, and retina. It is characterised by decreased nitric oxide bioavailability and increased endothelin-1. [11] Renal parenchymal disease, primary aldosteronism, renovascular disease, obstructive sleep apnea, or pharmaceutical reasons (NSAIDs, oral contraceptives, decongestants) can all induce secondary hypertension, which accounts for 5–10% of cases and necessitates pharmacist awareness and screening. [12]

Challenges in Hypertension Management

The asymptomatic aspect of hypertension—often referred to as the "silent killer"—makes therapeutic management of the condition difficult and leads to poor health-seeking behaviour and medication cessation. [13] A major factor in inadequate population-level management is therapeutic inertia, which is the inability of physicians to step up antihypertensive medication when blood pressure goals are not reached. [14]
The most common modifiable obstacle to reaching target blood pressure is medication non-adherence, which affects 40–60% of hypertension patients and is caused by pill burden, side effects, expense, and insufficient patient education. [15] A number of comorbidities, including diabetes, CKD, dyslipidaemia, and heart failure, make choosing medications more difficult and require that antihypertensive regimes be carefully tailored to each patient. [16] Accurate classification of white-coat hypertension and masked hypertension necessitates ambulatory or home blood pressure measures, which further complicate diagnosis and monitoring. [17]

Table 1. Blood Pressure Classification and Corresponding Pharmacist Action (ACC/AHA 2017)

Bp category	Systolic (mmHg)		Diastolic (mmHg)	Pharmacist Action
Normal	< 120	*AND*	< 80	Lifestyle counseling, annual screening
Elevated	120–129	*AND*	< 80	Non-pharmacological intervention, 3–6 month follow-up
Stage 1 HTN	130–139	*OR*	80–89	10-yr CVD risk assessment; MTM initiation
Stage 2 HTN	≥ 140	*OR*	≥ 90	Drug therapy + lifestyle; urgent referral if needed
Hypertensive Crisis	≥ 180	*AND/OR*	≥ 120	Immediate referral; withhold nephrotoxic agents

ACC/AHA = American College of Cardiology/American Heart Association; CVD = Cardio vascular Disease; MTM = Medication Therapy Management; HBPM = Home Blood Pressure Monitoring

Role of the Clinical Pharmacist

Clinical pharmacists work at the nexus of research and patient care, customising, monitoring, and optimising antihypertensive treatment using evidence-based pharmacotherapy principles. [4] They work on telemedicine platforms, community pharmacies, ambulatory care clinics, hospital inpatient units, and primary prevention through secondary risk reduction. [3] Comprehensive medication review (CMR), detection of drug treatment problems (DTPs), dosage optimisation, drug interaction screening, and ADR surveillance are all ways that pharmacists contribute special value, as acknowledged by the Joint National Committee and the American College of Clinical Pharmacy (ACCP). [18] In many jurisdictions, pharmacists can now independently start, adjust, and stop antihypertensive therapy—a model linked to better blood pressure control and patient satisfaction—thanks to the growing scope of pharmacist practice through collaborative practice agreements (CPAs) with physicians. [19]

Table 2. Summary of Key Clinical Pharmacist Roles in Hypertension Management

	Pharmacist Role	Key Activities
⚕	**Medication Review**	CMR, DRP identification, deprescribing
	Guideline Application	JNC 8, ACC/AHA 2017, ESC 2023 adherence
	Drug Therapy Optimization	Dose titration, combination therapy, switches
	BP Monitoring	HBPM, ABPM interpretation, white-coat HTN
	Risk Stratification	10-yr ASCVD risk, target organ damage assessment
	Collaborative Practice	CPA-based prescribing, team-based care

🖩	**Technology Integration**	Telepharmacy, mHealth apps, EHR alerts
🎓	**Patient Education**	Health literacy, SMBP technique, diet & exercise

CMR = Comprehensive Medication Review; CPA = Collaborative Practice Agreement; ABPM = Ambulatory Blood Pressure Monitoring; SMBP = Self-Measured Blood Pressure

Clinical Pharmacist Interventions

- **Medication Therapy Management (MTM)**
  A thorough medication review, a personal medication record, a medication action plan, intervention/referral, and documentation are the five main components of MTM, an organised service provided by pharmacists. [20] MTM addresses cost-related non-adherence, adverse medication events, drug duplication, and subtherapeutic doses in hypertension. In community and ambulatory settings, pharmacist-conducted MTM has been demonstrated to reduce uncontrolled hypertension by up to 20% and the average number of drug therapy issues per patient by 2.4. [21] For elderly hypertensive patients who are burdened by polypharmacy, deprescribing—the methodical removal of unnecessary medications—is an essential MTM component. [22] Reduced readmission rates and better BP goal attainment in the 30-day post-discharge period are linked to pharmacist-led medication reconciliation at care transitions (hospital discharge, outpatient follow-up). [23]
- **Patient Education and Counselling**
  The justification for antihypertensive medication, accurate self-measurement of blood pressure (SMBP), dietary modifications (DASH diet, sodium restriction <2.3 g/day), physical activity goals (150 min/week of moderate-intensity exercise), alcohol moderation, quitting smoking, and weight management are all components of effective pharmacist patient counselling. [24] Patient knowledge scores and self-management behaviours have been demonstrated to be considerably improved by health literacy-tailored education that uses teach-back techniques and culturally appropriate materials. [25]
  Treatment discontinuation and ER visits are decreased by counselling on identifying and treating common antihypertensive side effects, such as orthostatic hypotension (alpha-blockers, diuretics), ACEI-induced cough, angioedema (switching to ARB), ankle oedema (calcium channel blockers), and electrolyte disturbances (thiazide diuretics). [26]
- **Monitoring Blood Pressure**
  In order to distinguish between genuine hypertension, white-coat hypertension, and masked hypertension, clinical pharmacists are educated to measure and interpret clinic blood pressure, home blood pressure monitoring (HBPM), and ambulatory blood pressure monitoring (ABPM) data. [17] In order to obtain a more comprehensive and representative blood pressure profile for therapeutic decision-making, pharmacist-run blood pressure monitoring clinics, such as point-of-care testing programs in community pharmacy settings, provide blood pressure measurement outside of regular medical office hours. [27] The validity of SMBP data used to direct therapy modifications depends on pharmacist supervision on the appropriate home blood pressure measuring technique, which includes morning and evening measurements, standardised arm posture, validated equipment, and a 5-minute break before measurement. [28]
- **Techniques for Increasing Adherence**
  Motivational interviewing, pill box dispensing, blister packs, fixed-dose combination products (which reduce pill burden), automatic refill reminders, and simpler dosing regimens are just a few of the many tool's pharmacists use to improve prescription adherence. [29] Compared to free combinations, the usage of fixed-dose combination antihypertensive medications (such as amlodipine/valsartan and perindopril/indapamide) has been demonstrated to increase adherence by 23–33%. Pharmacists are crucial in helping patients make these conversions. [30]
  In a variety of hypertensive patients, pharmacist-led adherence programs that use electronic monitoring (MEMS caps), refill data analysis (PDC ≥0.80 as the adherence threshold), and scheduled follow-up phone calls have shown persistent adherence improvement over a 12-month period. [31]
- **Management of Adverse Drug Reactions**
  Antihypertensive drugs, which include symptomatic hypotension, electrolyte imbalances, renal impairment, sexual dysfunction, and drug interactions, are among the most frequent causes of avoidable adverse drug reactions (ADRs) in outpatient settings. [32] Using standardised tools like the Liverpool Drug Interaction Checker, the Naranjo Adverse Drug Reaction Probability Scale, and serum electrolyte/creatinine monitoring schedules, pharmacists routinely screen for ADRs at every patient interaction. [26]
  Pharmacist-identified drug interactions that impact blood pressure regulation is especially significant: NSAIDs reduce the effectiveness of antihypertensive medications, sympathomimetics increase blood pressure, and CYP3A4 inhibitors raise calcium channel blocker plasma levels. [33] Hospitalisations, ER visits, and needless treatment discontinuations due to antihypertensive medication toxicity are significantly decreased when pharmacists identify and treat ADRs early. [32]

- **Effect on Results**

  There is ample evidence of the therapeutic benefits of pharmacist participation in the treatment of hypertension. When compared to standard care, pharmacist interventions regularly result in mean reductions in SBP of 7–10 mmHg and DBP of 3–5 mmHg, which are clinically comparable to starting an extra antihypertensive medication, according to meta-analyses. [34]

  Based on recognised Framingham risk connections between blood pressure reduction and cardiovascular event rates, improved blood pressure control mediated by pharmacist intervention translates into estimated reductions in stroke risk by 35–40%, myocardial infarction by 20–25%, and all-cause mortality by 10–15%. [7] Several cost-effectiveness analyses show favourable incremental cost-effectiveness ratios (ICERs) well below recognised willingness-to-pay thresholds, further supporting the economic value of pharmacist involvement. These outcomes include decreases in hypertension-related emergency visits, hospitalisations, and total medication costs. [8]

Clinical Study Evidence

Pharmacist-led interventions in community settings significantly improved blood pressure control at 9 months (48% vs. 31% for usual care, p<0.001), and the effects persisted at the 24-month follow-up, according to the seminal CAPTION trial. [35] The Asheville Project also demonstrated that, over a five-year period, a considerably higher percentage of patients receiving pharmacist treatment achieved blood pressure management (<140/90 mmHg) than controls. [36]

Pharmacist-led interventions significantly improved blood pressure management (RR 1.19; 95% CI 1.12–1.27) and medication adherence when compared to standard physician care, according to a Cochrane systematic review of 39 RCTs involving 14,224 hypertensive patients. [3] When compared to standard care over a 12-month period, the TEAMCARE trial, which assessed pharmacist-physician collaborative management of co-occurring diabetes and hypertension in primary care, showed reductions in SBP of 5.5 mmHg and HbA1c of 0.5%. [36]

International data includes the Canadian PHARMACIST study, which showed that pharmacist case management services significantly lowered 10-year Framingham cardiovascular risk scores while also improving blood pressure, cholesterol, and smoking rates. [4] The efficacy of pharmacist-led hypertension programs in settings with limited resources is further demonstrated by data from China, India, and sub-Saharan Africa, highlighting the need for pharmacy-driven treatment models worldwide. [5]

Models of Collaborative Practice

The most sophisticated integration of pharmacists in the treatment of hypertension is represented by collaborative drug therapy management (CDTM) through formal CPAs, which allows pharmacists to independently start antihypertensive therapy, titrate doses to BP targets, order monitoring labs, and refer patients to specialists without the need for a prescriber to be present. [19] Compared to 60–65% in comparison locations, CPA-based pharmacist hypertension management programs in Veterans Affairs, Kaiser Permanente, and federally designated health institutions in the US have routinely attained control rates of 80%. [35]

Clinical pharmacists are formally integrated into primary care teams under the Patient-Cantered Medical Home (PCMH) and Accountable Care Organisation (ACO) models, which match financial incentives with BP control quality indicators. [18] Joint case conferences, standardised handoff procedures, shared electronic health record data, and collaborative rounds between pharmacists and physicians improve the quality and continuity of hypertension management along the care continuum. [33]

Role in Special Populations

Given the hazards of polypharmacy, orthostatic hypotension, falls, and cognitive impairment, managing hypertension in older persons requires specific pharmacist knowledge. [22] To identify incorrect antihypertensive treatment in older patients (e.g., avoiding alpha-blockers as first-line), pharmacists use the Beers Criteria and STOPP/START tools. They also customise blood pressure targets to take frailty and comorbidity burden into consideration. [22]

Pharmacists advise on the safety of labetalol, nifedipine, and methyldopa as recommended medicines during pregnancy; they also make sure that ACEIs, ARBs, and direct renin inhibitors are avoided owing to fetotoxicity. [12] Pharmacists must consider metabolic consequences while choosing and optimising antihypertensives for patients with diabetes. While RAAS inhibitors offer dual cardiorenal protection, thiazide diuretics and beta-blockers may compromise glycaemic management. [16] Pharmacists screen for secondary causes, evaluate medication adherence, detect drug interactions, and promote prompt expert referral in cases of resistant hypertension (BP >130/80 mmHg despite appropriate three-drug therapy). [13]

Use of Technology

In rural and underprivileged regions, tele pharmacy services—synchronous video consultations and asynchronous messaging platforms—have increased pharmacist access to hypertension patients and shown comparable blood pressure decreases to in-person visits. [27] By integrating mobile health (mHealth) apps with Bluetooth-enabled blood pressure monitors, pharmacists can provide proactive rather than reactive care by reviewing real-time blood pressure readings, creating trend analysis, and communicating medication modifications asynchronously. [28]

Clinical decision support (CDS) solutions integrated into electronic health records (EHRs) enable population-level hypertension surveillance by alerting pharmacists to uncontrolled blood pressure, missing medication refills, drug interactions, and required laboratory testing. [31] Pharmacists will play a crucial role in interpreting and implementing precision hypertension pharmacotherapy as artificial intelligence (AI) and machine learning algorithms are increasingly being developed to predict antihypertensive treatment response based on patient genotype, demographics, and comorbidities. [29]

Barriers to Pharmacist-Led Hypertension Management

Pharmacist incorporation into hypertension treatment teams is hindered by structural and organisational hurdles, despite compelling evidence. Full-scope practice is constrained by the lack of institutional CPA infrastructure, the absence of independent prescription authority in many countries, and the limited acknowledgement of pharmacy services by third-party payers. [20] Healthcare organisations are financially discouraged from integrating clinical pharmacists into hypertension programs because of inconsistent reimbursement for MTM and clinical pharmacy services under public and private insurance schemes. [21] Pharmacist time constraints at the practice level make it difficult to do comprehensive BP tests and counselling, especially in high-volume community dispensing settings. [25] Health literacy deficiencies, language difficulties, the digital gap that affects technology-enabled interventions, mistrust of non-physician doctors, and financial obstacles to medicine availability are examples of patient-level barriers. [24] The depth of pharmacist skill in complex hypertension situations is further limited by gaps in postgraduate nephrology and cardiology training within pharmacy courses. [18]

Prospective Views

A number of encouraging advancements will influence pharmacist-led hypertension treatment in the future. Pharmacists will be able to autonomously manage simple hypertension from commencement to long-term maintenance thanks to the widespread adoption of pharmacist prescribing authority, which has already been established in Canada, the UK, and New Zealand. [19] Pharmacogenomic testing will reduce the existing trial-and-error method of drug selection by enabling pharmacists to customise antihypertensive choices based on CYP2D6, ADRB1, and ACE gene polymorphisms. [33]

Pharmacists will be able to manage dynamic, real-time treatment titration protocols in collaboration with patients thanks to pharmacist decision assistance and wearable continuous blood pressure monitoring devices (cuffless technology). [29] Scaling these interventions for population-level impact will need the creation of performance-based pharmacy reimbursement models linked to BP control quality indicators and the integration of pharmacist-provided hypertension care into international non-communicable disease frameworks. (35)

Conclusion

The worldwide epidemic of hypertension continues to call for creative, patient-centred, team-based solutions. With a strong and expanding body of evidence, clinical pharmacists are well-positioned to improve hypertension management outcomes through MTM, patient education, adherence optimisation, collaborative prescribing, technology-enabled monitoring, and individualised care for unique populations. [3] Clinically significant, long-lasting decreases in blood pressure and cardiovascular risk result from their incorporation into hypertension care teams, from community pharmacies to speciality clinics. Addressing reimbursement disparities, increasing prescribing authority, funding advanced training, and embracing digital health innovation are all necessary to fully realise the potential of clinical pharmacy in hypertension. [4] It is a public health necessity, not just evidence-based advice, to put the clinical pharmacist at the core of managing hypertension.

References

1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127–248.
2. World Health Organization. Global report on hypertension: the race against a silent killer. Geneva: WHO; 2023.
3. Santschi V, Chiolero A, Paradis G, Colosimo AL, Burnand B. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabet Care. 2012;35(12):2706–17.
4. Tsuyuki RT, Houle SK, Charrois TL, et al. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation. 2015;132(2):93–100.
5. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37.
6. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165–82.
7. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–49.
8. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.
9. Oparil S, Acelajado MC, Bakris GL, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014.
10. Touyz RM, Montezano AC. Vascular Nox4: a multifarious NADPH oxidase. Circ Res. 2012;110(9):1159–61.
11. Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension. 2012;59(2):367–74.
12. Puar THK, Mok Y, Debajyoti R, Khoo J, How CH, Ng AK. Secondary hypertension in adults. Singapore Med J. 2016;57(5):228–32.
13. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Hypertension. 2008;51(6):1403–19.
14. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57(6):1076–80.
15. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.

16. American Diabetes Association. Standards of medical care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S1–291.

17. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2013;31(7):1281–357.

18. American College of Clinical Pharmacy. The definition of clinical pharmacy. Pharmacotherapy. 2008;28(6):816–7.

19. Houle SKD, Charrois TL, Faruquee CF, Tsuyuki RT, Campbell NRC. Pharmacist prescribing of antihypertensives: an assessment of 1-year follow-up of the RxACTION randomized controlled trial. Can Pharm J. 2017;150(4):248–54.

20. American Pharmacists Association; National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc. 2008;48(3):341–53.

21. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007;41(10):1569–82.

22. American Geriatrics Society 2023 updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71(7):2052–81.

23. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955–64.

24. Whelton PK, Appel LJ, Sacco RL, et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation. 2012;126(24):2880–9.

25. Nutbeam D. Health literacy as a public health goal: a challenge for contemporary health education and communication strategies into the 21st century. Health Promot Int. 2000;15(3):259–67.

26. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.

27. Pinto SL, Kumar J, Partha G, Bechtol RA. Pharmacist-provided medication therapy management (MTM) program impacts outcomes for hypertensive patients in the community pharmacy setting. Pharm Pract (Granada). 2014;12(3):430.

28. Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293–302.

29. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.

30. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.

31. Krousel-Wood M, Joyce C, Holt E, et al. Predictors of decline in medication adherence: results from the Cohort Study of Medication Adherence Among Older Adults. Hypertension. 2011;58(5):804–10.

32. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–12.

33. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the Management of Arterial Hypertension. J Hypertens. 2023;41(12):1874–2071.

34. Rash JA, Lavoie KL, Belanger M, et al. Systematic review and meta-analysis of pharmacist-led hypertension management. Can Pharm J. 2017;150(5):311–25.

35. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310(1):46–56.

36. Heisler M, Hofer TP, Schmittdiel JA, et al. Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems. Circulation. 2012;125(23):2863–72.